8-K


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported) – February 29, 2016
WEST PHARMACEUTICAL SERVICES, INC.
(Exact name of registrant as specified in its charter)

 
 
 
 
 
Pennsylvania
 
1-8036
 
23-1210010
(State or other jurisdiction
of Incorporation)
 
(Commission File Number)
 
(IRS Employer
Identification No.)
 
 
 
 
 
530 Herman O. West Drive, Exton, PA
 
 
 
19341-0645
(Address of principal executive offices)
 
 
 
(Zip Code)

 Registrant’s telephone number, including area code: 610-594-2900

Not Applicable
(Former name or address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 





Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

After 19 years of dedicated service, Anthony Welters informed West Pharmaceutical Services, Inc. (the "Company") on February 23, 2016 of his intention not to stand for re-election to the Company's Board of Directors at the next Annual Meeting of Shareholders, scheduled to be held on May 3, 2016 (the "Annual Meeting"), in order to pursue other interests. Mr. Welters will continue to actively serve on the Company's Board of Directors until the Annual Meeting. Mr. Welters has informed the Company that there is no disagreement between himself and the Company on any matter relating to its operations, polices or practices.

Also on February 23, 2016, after 36 years of dedicated service, John E. Paproski, Senior Vice President and Chief Technology Officer, informed the Company of his intention to retire from the Company effective as of April 1, 2016.









SIGNATURE


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



 
WEST PHARMACEUTICAL SERVICES, INC.
 
 
 
 
 
/s/ William J. Federici
 
William J. Federici
 
Senior Vice President and Chief Financial Officer
 
 
 
 
February 29, 2016